Relapsed or Refractory Multiple Myeloma
Conditions
Keywords
BCMA, Chimeric antigen receptor T cell, Adoptive cell therapy
Brief summary
This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.
Interventions
BIOLOGICALanti-BCMA CAR-T
Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
DRUGCyclophosphamid
300mg/m2/d
DRUGFludarabine
30mg/m2/d
Sponsors
Carbiogene Therapeutics Co. Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with relapsed/refractory multiple myeloma aged 18-75 years; 2. BCMA expression ≥50% in bone marrow samples confirmed by Flow Cytometry or IHC is positive for BCMA expression; 3. Relapsed/refractory patients who meet the following conditions: 1. Ineffective or disease progression after receiving bortezomib (proteasome inhibitor) and lenalidomide for 3 courses; 2. Ineffective or disease progression after receiving the original treatment plan for 3 courses; 3. The interval between the last treatment and disease progression is more than 30 days; 4. There is currently no indication for hematopoietic stem cell transplantation, or the patient refuses to do hematopoietic stem cell transplantation; 5. The definition of disease progression refers to the 2014 IMWG Standards, and at least meets the following 1 items: e.1 Serum M protein ≥ 0.5 g/dL; e.2 Urine M protein ≥ 200 mg/24 h; e.3 If the serum FLC ratio is abnormal, the patient's FLC level ≥ 10 mg/dL (100 mg/L); e.4 Evaluable plasmacytoma confirmed by biopsy; e.5 Increase in the proportion of bone marrow plasma cells ≥25% (absolute increase ≥10%); e.6 Bone marrow plasma cells account for 30% of the total bone marrow cells; 4. Estimated survival time\> 12 weeks; 5. The disease status can be assessed and meet at least one of the following: 1. Serum M-protein ≥10 g/L; 2. 24h urine M-protein ≥200mg; 3. Serum FLC≥5mg/dL; 4. Plasma cell tumors that can be assessed by testing or images; 5. The proportion of bone marrow plasma cells ≥ 30%; 6. ECOG physical status score 0-1; 7. Have enough venous access for apheresis or venous blood collection, and there are no other contraindications for blood cell separation; 8. WBC ≥ 1.5×109/L; PLT ≥ 45×109/L; 9. Serum creatinine ≤ 1.5 upper limit of normal (ULN) ; 10. ALT ≤ 2.5 ULN, AST ≤ 2.5 ULN. All laboratory test results within the above range should have no ongoing continuous supportive treatment.
Exclusion criteria
\- Subjects who meet any of the following criteria cannot be selected for this study: 1. Systemic treatment such as lymphatic depletion with cyclophosphamide and fludarabine within 2 weeks before enrollment or single cell collection, or cell therapy within 8 weeks before treatment; 2. HCV or HIV positive; any uncontrollable active infection, including active tuberculosis, HBV DNA level ≥1×103 copies/mL; 3. Active infections occurred within 72 hours before cleansing; as long as there is no evidence of active infection and antibiotics are not in the list of prohibited drugs, subjects who continue to use preventive antibiotics, antifungal drugs or antiviral drugs are not excluded; 4. The current systemic use of cyclosporine or steroid drugs such as dexamethasone, recent or current use of inhaled steroids is not excluded; 5. Renal insufficiency, serum creatinine\>1.5 upper limit of normal (ULN); 6. Liver insufficiency, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)\>2.5 times ULN and direct bilirubin\>1.5 times ULN; 7. Hyponatremia, blood sodium \<125 mmol/L; 8. Baseline serum potassium \<3.5 mmol/L (potassium supplementation can be given before participating in the study, and serum potassium recovery above this standard is not excluded); 9. Pregnant or lactating women; 10. Other serious diseases that may restrict subjects from participating in this trial (such as central nervous system disease, severe heart insufficiency, myocardial obstruction or unstable arrhythmia or unstable angina, gastric ulcer in the past 6 months , Active autoimmune diseases, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of grade 3 or 4 treatment related adverse effect | 24 weeks after last dose of CAR-T treatment | All the CAR-T treatment related adverse events，including Dose limiting toxicity (DLT), cytokine release syndrome (CRS), CAR-T associated encephalopathy syndrome, will be assessed and graded by NCI CTCAE v 5.0. |
| Overall response rate (ORR) after treated by CAR-T treatment | up to 2 years after CAR-T treatment | ORR will be assessed and graded by the international Myeloma Working Group (IMWG) Unified response criteria for multiple myeloma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of CAR-T cells (implantation endpoint) | up to 2 years after CAR-T treatment | To assess the duration of CAR-positive T cells in circulation, the copy number of CAR DNA was measured at the preset follow-up time point. The time when the results of any two consecutive tests were negative, were recorded as the implantation endpoint. |
| Overall survival | up to 2 years after CAR-T treatment | From date of inclusion to date of progression, relapse, or death from any cause. |
| Progression free survival | up to 2 years after CAR-T treatment | The length of time that a participant's disease did not progress during and after CAR-T treatment. |
Countries
China
Contacts
Primary ContactWenbin Qian
Outcome results
None listed